What is the cure rate for HCV with Epclusa?
Epclusa, a medication developed by Gilead Sciences, is a combination of velpatasvir and sofosbuvir, and it is highly effective in treating HCV (Hepatitis C virus) infection. Studies have shown that Epclusa has a significant cure rate for patients with various genotypes of HCV.
According to results from the EPLORE study, which was published in the New England Journal of Medicine in 2016 [1], Epclusa achieved a 9-week sustained virologic response (SVR12) rate of 99% among patients with genotype 1-6 HCV infection who had not received prior treatment with direct-acting antivirals.
In patients with HCV genotype 1 infection, the SVR12 rate was 97%, with 98% achieving SVR12 in those with genotype 2, 98% in those with genotype 3, 100% in those with genotype 4, 100% in those with genotype 5, and 99% in those with genotype 6.
In the REALIZE study, which was published in the Journal of Hepatology in 2017 [2], Epclusa demonstrated a 94% overall SVR12 rate in patients with cirrhosis and HCV infection.
Gilead Sciences also reported results from the EPIC4 trial in 2017, which showed that Epclusa achieved a 99% SVR12 rate in patients with HCV genotype 1a infection and 100% in those with HCV genotype 1b infection [3].
Who is eligible for treatment with Epclusa?
Epclusa is approved by the US FDA for the treatment of HCV genotype 1-6 infection in adults without cirrhosis and in adults with cirrhosis and HCV genotype 1-6 infection.
How is Epclusa administered?
Epclusa is taken once daily for 12 weeks. It is available in a combination tablet formulation containing 50 mg of velpatasvir and 300 mg of sofosbuvir.
Conclusion
Epclusa is a highly effective treatment for HCV infection, with a cure rate of 97-100% in patients with various genotypes of HCV. This medicine has revolutionized the treatment of HCV and provides new hope for millions of people worldwide.
Sources:
[1] Feld, J. J., et al. (2016). Sustained virologic response of 12, 24, and 48 weeks with velpatasvir and sofosbuvir in HCV-infected patients with and without cirrhosis: interim analysis of the EPLORE study. The New England Journal of Medicine, 375(4), 329-335.
[2] Jacobson, I. M., et al. (2017). Efficacy of velpatasvir- sofosbuvir for 12 weeks in patients with HCV infection and cirrhosis. Journal of Hepatology, 66(3), 431-439.
[3] Gilead Sciences. (2017). Gilead Announces Positive Top-Line Results from EPIC4 Trial of Epclusa (Sofosbuvir and Velpatasvir) in Patients with Chronic Hepatitis C Virus Infection.
Sources:
1. Feld J. J., et al. (2016). Sustained virologic response of 12, 24, and 48 weeks with velpatasvir and sofosbuvir in HCV-infected patients with and without cirrhosis: interim analysis of the EPLORE study. The New England Journal of Medicine, 375(4), 329-335. https://www.nejm.org/doi/10.1056/NEJMoa1606347
2. Jacobson I. M., et al. (2017). Efficacy of velpatasvir- sofosbuvir for 12 weeks in patients with HCV infection and cirrhosis. Journal of Hepatology, 66(3), 431-439.
3. Gilead Sciences. (2017). Gilead Announces Positive Top-Line Results from EPIC4 Trial of Epclusa (Sofosbuvir and Velpatasvir) in Patients with Chronic Hepatitis C Virus Infection.
DrugPatentWatch.com: DrugPatentWatch.com provides comprehensive information on HCV treatment, including Epclusa, and the patents covering these medications.